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ABSTRACT
Background and aims: The extent and molecular
mechanisms governing plasma extravasation and forma-
tion of ascites in cirrhosis are unknown. Vascular
endothelial growth factor-A (VEGF-A) and angiopoietin-2
(Ang-2) are endogenous substances with powerful
vascular permeability effects. We assessed regional blood
flow, vascular leakage, mRNA and tissular expression of
VEGF-A and Ang-2 and vascular permeability following
VEGF receptor 2 blockade in control and cirrhotic rats to
define the vascular territories showing altered vascular
permeability in cirrhosis and to determine whether VEGF-
A and Ang-2 are involved in this phenomenon.
Methods: Arterial blood flow was analysed with the
coloured microsphere method. Vascular leakage was
measured and visualised with the dye Evan’s Blue and
colloidal carbon techniques, respectively. VEGF-A and
Ang-2 expression were determined by real-time poly-
merase chain reaction (RT-PCR), immunohistochemistry
and western blot. The effect on vascular permeability
induced by VEGFR2 blockade was assessed by adminis-
tration of the receptor inhibitor SU11248.
Results: Arterial blood flow was increased in the
mesentery, pancreas and small intestine but not in the
kidney and spleen of cirrhotic rats as compared to
controls. Increased vascular leakage was observed in the
mesentery and liver, where colloidal carbon spread from
microvessels to the adjacent fibrotic tracts. Increased
hepatic and mesenteric expression of VEGF-A and Ang-2
was found in cirrhotic rats as compared to controls.
Blockade of VEGFR2 markedly reduced hepatic and
mesenteric vascular leakage in cirrhotic rats.
Conclusions: Enhanced endothelial permeability is
restricted to the hepatic and mesenteric vascular beds in
cirrhotic rats with ascites and VEGF-A and Ang-2 are key
factors in the signalling pathways regulating this
dysfunction.
Ascites, the most common complication in
patients with advanced liver disease, is invariably
associated with portal hypertension and consists of
the accumulation of liquid in the peritoneal cavity.1
Ascites in cirrhotic patients is mainly formed by
salt and water, variable amounts of albumin and
globulins, and a relatively low number of mesothe-
lial cells and leucocytes. Because of this relatively
simple composition the presence of ascites was
classically considered to have little or no influence
on the homeostasis of the peritoneal vasculature.
Nevertheless, this has recently been challenged by
several studies demonstrating that this liquid
may possess vasodilator, proinflammatory and
proangiogenic properties.2–7 However, whereas it
is well documented that ascites in cirrhosis may
behave as a bioactive fluid, the source of this liquid
and the molecular gates regulating fluid extravasa-
tion in cirrhosis are less clear. Several pieces of
circumstantial evidence point to the cirrhotic liver
as an important source of ascites8 9 but discussion
still exists concerning the relative contribution of
other organs located in the abdominal cavity, such
as the intestine, spleen, pancreas or the mesenteric
vasculature. On the other hand, vascular leakage
depends on a number of variables including the
physical properties of the fluid or the molecule
being transported and the gradients between the
intra- and the extravascular compartments.10
Moreover, transvascular transport may occur
through channels or vesicles within individual cells
or through inter-endothelial junctions between
adjacent cells.11 Endothelial cells are the primary
barrier to vascular extravasation, thus regulating
the passage of molecules by a variety of mechan-
isms that are chiefly regulated by the initially
called vascular permeability factor and now better
known as the vascular endothelial growth factor
type A (VEGF-A). This peptide belongs to the
VEGF family which comprises five additional
known members of structurally related dimeric
glycoproteins: VEGF-B, VEGF-C, VEGF-D, VEGF-E
and placental growth factor (PlGF). In addition,
alternative exon splicing of the VEGF-A gene
generates at least five VEGF isoforms, with 121,
145, 165, 189 or 206 amino acid residues with
different bioavailability and with VEGF-A121 and
VEGF-A165 being the most frequently expressed
forms.12 This family of growth factors binds and
activates three VEGF transmembrane tyrosine
kinase receptors: VEGFR1 (vascular endothelial
growth factor receptor 1), VEGFR2 and VEGFR3,
which differ in their ligand specificities.12 By
interacting with the VEGFR2, VEGF-A not only
induces angiogenesis but also disrupts vascular
barrier function in diseased tissues.10 11 The list of
angiogenic substances that increase vascular per-
meability in vivo has recently been enlarged by
angiopoietin-2 (Ang-2), a member of the angio-
poietin family of proteins that dose-dependently
induces oedema formation in the mouse paw
assay.13 Angiopoietin-1 (Ang-1) is a Tie-2 receptor
agonist that induces pericyte recruitment and
maturation of blood capillaries. Then, capillary
endothelial cells become quiescent and unrespon-
sive to VEGF-A action unless Ang-2 is also secreted.
Therefore, Ang-2 is a natural Ang-1 antagonist
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which displaces Ang-1 from its receptor, thereby disrupting Tie-
2 signalling.14 However, the contributory role of VEGF-A and
Ang-2 to vascular leakage and oedema formation in cirrhosis is
unknown. Identification of the source and molecular mechan-
isms governing vascular hyperpermeability in cirrhosis may
potentially favour future strategies to reduce tissue injury in
these patients.
MATERIALS AND METHODS
Animals
This study was performed in 38 male adult cirrhotic Wistar rats
and in 23 control Wistar rats (Charles–River, Saint Aubin les
Elseuf, France). Both groups were fed ad libitum with standard
chow and distilled water containing phenobarbital. Cirrhosis
was induced as described elsewhere.15 Cirrhotic rats without
ascites were studied between 12 and 14 weeks and cirrhotic rats
with ascites between 13 and 18 weeks. When present, ascites
was tested for bacterial culture and was negative in all cirrhotic
rats included in the study. Control rats were studied following a
similar period of phenobarbital administration.
Measurement of vascular permeability
The dye Evan’s Blue (EB; Sigma Chemical, St Louis, Missouri,
USA) technique was used to measure capillary permeability to
albumin. This technique is based on the principle that this dye
binds avidly to the negatively charged intravascular albumin,
therefore being a reliable estimate of transvascular fluxes of
macromolecules.16 The dye was quantified by spectrophotome-
try at 620 nm and the results were calculated from a standard
curve of Evan’s Blue (0.05–25 mg/ml) and expressed as mg EB/g
dry weight of tissue.
Identification of hyperpermeable blood vessels of tissues and
organs with colloidal carbon
Colloidal carbon is a tracer that can be visualised in tissues by
both macroscopy and high-resolution light microscopy.17
Control and cirrhotic rats with ascites were anaesthetised with
ketamine (50 mg/kg) and injected intravenously (i.v.) with
2 ml/kg body weight of a 1:5 dilution (in PBS) of colloidal
carbon (C11/1431A, Guenther Wagner, Hannover, Germany).
One hour later, animals were killed by CO2 narcosis and liver
specimens obtained from the middle lobe, the mesentery with
the attached bowel, pancreas, spleen and right kidney were
fixed in 4% formaldehyde. Liver, spleen and kidney were
embedded in paraffin and processed for Giemsa staining.
Tissue slides were visualised by high-resolution light microscopy
(Olympus Bx51, Tokyo, Japan). Mesentery–bowel and pancreas
were mounted under PBS immersion for viewing in a macro-
scope (MZ6; Leica Microsystems, Heerbrugg, Switzerland).
Measurement of haemodynamic parameters
See supplementary data.
mRNA expression of VEGF-A and Ang-2 in abdominal organs of
cirrhotic rats
See supplementary data.
Western blot of VEGF-A, Ang-1, Ang-2 and phosphorylated
VEGFR2 and immunohistochemistry of VEGF-A and Ang-2
See supplementary data.
Effect of VEGFR2 blockade on vascular permeability
To test whether VEGFR2 mediates vascular hyperpermeability
in cirrhotic animals, 10 rats with cirrhosis and ascites were
anaesthetised with inactine (100 mg/kg) and randomly received
an oral administration of the VEGFR2 antagonist SU11248
(n = 5; 20 mg/kg body weight) or vehicle (n = 5; citrate-
buffered solution, pH 3.5). After 2.5 h, vascular permeability
was assessed in both groups of animals as described above and
liver samples were frozen at 280uC to further analyse VEGFR2
phosphorylation.
Statistical analysis
Data are expressed as mean with the SE. Statistical analysis of
the results was performed by one-way analysis of variance
(ANOVA) the Newman–Keuls test, and the unpaired Student t
Figure 1 Measurement of vascular leakage in abdominal tissues with the Evan’s Blue (EB) dye method. Animals were anaesthetised with ketamine
(50 mg/kg) and injected in the penile vein with Evan’s Blue (30 mg/kg) which was allowed to circulate for 30 min. The dye was washed out by
perfusing the vascular tree with phosphate-buffered saline (PBS) containing heparin (50 U/ml) for 5 min and then the vasculature was perfusion-fixed
(1% paraformaldehyde in 50 mmol/l citrate buffer, pH 3.5) for 2 min at a constant flow of 100 ml/min. The liver, mesentery, right kidney, spleen, small
intestine and pancreas were obtained from control rats (CT, n = 8) cirrhotic rats without ascites (CH, n = 5) and cirrhotic rats with ascites (CH+A,
n = 8) to assess the degree of vascular extravasation. The amount of the extracted dye was expressed as micrograms of Evan’s Blue per gram of dry
weight of each tissue. ***p,0.001; **p,0.01 and *p,0.05 vs control rats (one-way ANOVA and Newman–Keuls tests).
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test when appropriate. Differences were considered to be
significant at a p value of 0.05 or less.
RESULTS
Vascular permeability in intra-abdominal tissues
Basal leakage of Evan’s Blue varied from one organ to other,
ranging between 235.8 (SE 61.5) mg EB/g tissue in the spleen and
8.3 (SE 0.8) mg EB/g tissue in the mesentery. These fluctuations
in basal permeability among the different organs are not
uncommon and have been shown to depend on the degree of
vascularisation of these organs.18 It is important to stress that
the albumin-bound Evan’s Blue remaining within the vascular
compartment after tissue washout is considered to be negli-
gible.18 Figure 1 shows plasma extravasation in the liver,
mesentery, kidney, spleen, small intestine and pancreas of
control and cirrhotic rats, without and with ascites. A marked
increase in plasma permeability was found in the liver and
Figure 2 Giemsa-stained sections
illustrating microvascular permeability in
the liver of control and cirrhotic rats
(upper panels). Low-power macrographs
of leaky blood vessels of mesentery and
pancreas of control and cirrhotic rats are
also shown in the middle and lower
panels, respectively. Colloidal carbon was
injected intravenously and used as a
tracer of local extravasation. Original
magnifications: liver, 6200; mesentery,
610; and pancreas, 620.
Table 1 Systemic haemodynamics and arterial blood flow in the different organs in control and cirrhotic rats
included in the haemodynamic protocol
Control rats (n = 7) Cirrhotic rats (n = 7)
Systemic haemodynamics
Mean arterial pressure (mm Hg) 125 (1) 102 (1)*
Heart rate (beats/min) 371 (5) 374 (9)
Cardiac index (ml/min/100 g) 21.9 (0.5) 40.8 (2.9)**
Systemic vascular resistance (mm Hg min/ml) 5.72 (0.16) 2.59 (0.20)**
Regional blood flow (ml/min/100 g)
Liver 34.5 (5.2) 31.4 (5.4)
Mesentery 18.2 (2.8) 53.3 (10.6)*
Pancreas 59.3 (5.3) 160.3 (13.)**
Spleen 123.5 (18.4) 123.4 (16.6)
Small intestine 81.8 (13.5) 235.7 (40.0)*
Kidney 340.5 (43.6) 455.6 (36.4)
Results are given as mean (standard error).
*p,0.01 and **p,0.001 vs control rats.
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mesentery of cirrhotic rats with ascites as compared to controls,
with the differences between the two groups being 7-fold and
more than 2-fold higher, respectively. No differences in this
parameter were observed between the kidneys of cirrhotic and
control animals. In contrast, spleen, small intestine and
pancreas of rats with cirrhosis and ascites showed a tendency
towards decreased capillary permeability in comparison to
control rats, although differences only reached statistical
significance in the pancreas. In fact, extravasation of Evan’s
Blue in the pancreas of cirrhotic rats was around four times
lower than that in controls (fig 1). No differences were found in
vessel permeability between control animals and cirrhotic rats
without ascites in any of the organs in which this parameter
was assessed, with the exception of the pancreas in which vessel
permeability was reduced in comparison to control rats.
Identification of hyperpermeable blood vessels using colloidal
carbon
Colloidal carbon is a precise marker for identifying leaky blood
vessels at the ultrastructural level.19 Colloidal carbon particles
are able to penetrate hyperpermeable endothelium but are
retained by the underlying basal lamina if it is intact and
continuous. Therefore, vascular leakage can be identified by
deposits of colloidal carbon in the vascular basal lamina. No
significant differences were found in the labelling pattern of the
spleen, small intestine and right kidney between control and
cirrhotic animals (data not shown). In contrast, cirrhotic
animals displayed an altered distribution pattern of the tracer
in the liver, mesentery and pancreas as compared to control rats.
Figure 2 shows representative hepatic sections from a control rat
and a cirrhotic rat with ascites. Whereas in control rats colloidal
carbon was uniformly distributed over the liver parenchyma
and spread from the portal space towards the hepatic sinusoids,
in cirrhotic animals the presence of the tracer was more
abundant and its distribution did not follow a regular pattern.
It is of note that colloidal carbon was extensively located close
to or within the fibrous septa.
Paralleling the results obtained at quantifying the mesenteric
permeability, mesenteric vessels of cirrhotic rats became
markedly leaky to colloidal carbon. In these animals the tracer
escaped to the basal lamina, while in normal rats carbon
particles were practically all retained in the interior of the
mesenteric vasculature (fig 2). Thus, hepatic dysfunction is also
associated with increased endothelial fenestration in the
mesenteric vascular bed.
A final remarkable observation of this protocol was that the
abnormal colloidal carbon distribution pattern found in the
pancreas of cirrhotic rats followed an opposite direction to that
observed in the liver and mesentery of these animals. As shown
in fig 2, pancreatic vessels of control rats are highly permeable to
the tracer, which results in the identification of a dense vascular
network of capillaries. By contrast, this almost disappears on
analysing the pancreatic tissue of cirrhotic animals.
Systemic haemodynamics and arterial blood flow
Since changes in blood flow may modulate vascular perme-
ability,20 we next assessed systemic haemodynamics and arterial
blood flow in cirrhotic and control rats. As anticipated, cirrhotic
rats displayed an important hypercirculatory syndrome char-
acterised by arterial hypotension, high cardiac index and
markedly reduced systemic vascular resistance (table 1).
Moreover, cirrhotic rats also showed a significantly increased
arterial blood flow in the mesentery, pancreas and small
intestine while no differences were registered in the spleen,
kidney and liver. It should be noted, however, that total liver
blood flow has a dual component: the arterial blood flow and
the portal venous inflow, this latter parameter not being
measured when using the microsphere method to assess blood
flow. Since several studies have previously demonstrated an
enhanced portal venous inflow in humans and rats with
advanced liver disease,21 22 it is very likely that the total hepatic
blood flow was increased in our cirrhotic animals.
mRNA expression of VEGF-A and Ang-2 in intra-abdominal
tissues
Since VEGF-A and Ang-2 are two major regulators of micro-
vessel permeability, we next assessed whether organ perme-
ability dysregulations are associated with altered expression of
these messengers. As shown in table 2, changes in mRNA
expression of VEGF-A and Ang-2 followed a parallel pattern to
that observed in the analysis of regional alterations of vascular
permeability.
These transcripts were significantly enhanced in the liver and
mesentery of cirrhotic animals as compared to controls. In
contrast, a marked reduction in VEGF-A and Ang-2 mRNAs was
found in the pancreas of cirrhotic rats as compared to controls.
Interestingly, a highly significant increase in Ang-2 mRNA, but
not VEGF-A mRNA, was observed in the small intestine of
cirrhotic animals compared to control animals. Finally, no
differences in mRNA levels were observed between spleen and
kidney of cirrhotic and control animals.
VEGF-A and Ang-2 protein expression in the organs with altered
vascular permeability
Western blot analysis for VEGF-A in the liver showed two
bands at 38 kDa and 45 kDa corresponding to the VEGF121 and
VEGF165 isoforms, respectively (fig 3). Densitometric analysis
revealed increased VEGF-A protein content in cirrhotic livers as
compared to controls, which was due to a rise in the VEGF165
Table 2 Quantitative real-time polymerase chain reaction of vascular endothelial growth factor-A and
angiopoietin-2 in abdominal tissues of control and cirrhotic rats with ascites
Tissue
Vascular endothelial growth factor-A Angiopoietin-2
Control (n = 5) Cirrhosis (n = 5) Control (n = 5) Cirrhosis (n = 5)
Liver 1.14 (0.2) 1.91 (0.2)* 1.17 (0.2) 2.41 (0.4)*
Mesentery 1.09 (0.2) 5.59 (0.8)* 1.09 (0.1) 3.58 (0.6)*
Small intestine 1.07 (0.1) 1.55 (0.4) 1.17 (0.1) 4.36 (0.6)**
Pancreas 1.04 (0.2) 0.53 (0.1)* 1.17 (0.2) 0.57 (0.1)*
Spleen 1.07 (0.2) 0.89 (0.2) 1.07 (0.2) 1.49 (0.2)
Kidney 1.13 (0.1) 1.38 (0.1) 1.12 (0.2) 1.03 (0.2)
Results are given as mean (SE) for mRNA expression (fold change compared to reference controls).
*p,0.01 and **p,0.001 vs control rats.
Hepatology
288 Gut 2009;58:285–292. doi:10.1136/gut.2008.155028
 group.bmj.com on April 4, 2011 - Published by gut.bmj.comDownloaded from 
isoform. The protein signal of the VEGF121 isoform was similar
in both groups of animals. The densitometric analysis of VEGF-
A expression in the mesentery delivers qualitatively similar
conclusions, indicating increased abundance of VEGF-A in
cirrhotic animals. Conversely, western blot analysis of VEGF-
A in pancreatic homogenates resulted in an reduced expression
of this substance, thus mirroring the results found when
vascular permeability was assessed.
As shown in fig 4, the protein content of Ang-2 in the
different organs yielded very similar results to those obtained
with VEGF-A. Actually, the liver and mesentery of cirrhotic rats
showed enhanced abundance of Ang-2, whereas an acute
reduction of this peptide was noted in the pancreas of these
animals in comparison to controls. Moreover, and in agreement
with the results obtained on assessing mRNA expression, the
protein abundance of Ang-2 was significantly higher in the
small intestine than in controls. The protein content of Ang-1
was also assessed in the liver, mesentery, small intestine and
pancreas of control and cirrhotic rats. In agreement with
previous findings obtained in our laboratory,23 all these organs,
except the pancreas, showed increased abundance of Ang-1 in
cirrhotic rats with ascites compared with control animals (fig 5).
In an attempt to identify the cellular source of the altered
expression of vascular permeability factors, we performed
histological immunolocalisation of VEGF-A and Ang-2 in liver
and pancreas of cirrhotic and control rats. VEGF-A and Ang-2
immunolabelling was only detected in the first row of
perivenular hepatocytes of control rats. In cirrhotic animals,
most hepatocytes appeared as VEGF-A and Ang-2 positive cells
and no signal was detected in bile duct epithelial cells and
myofibroblasts (figs 6 and 7, respectively). Expression of VEGF-
A and Ang-2 in the pancreas of control rats was restricted to
cells located in the pancreatic islets of control animals and this
signal almost disappeared on examining pancreatic sections
from cirrhotic rats (figs 6 and 7, respectively).
Effect of VEGFR2 blockade on vascular leakage in cirrhotic rats
In a further attempt to establish a direct relationship between
the increased expression of vascular permeability factors and
altered tissue leakage in liver disease we assessed the effect of
acutely blocking VEGFR2 on vascular permeability in cirrhotic
rats with ascites. In vivo efficacy of SU11248 was assessed by
comparing hepatic VEGFR2 phosphorylation between treated
and untreated cirrhotic animals. As shown in supplementary
fig 1, VEGFR2 blockade almost suppressed the presence of the
phosphorylated form of this receptor in the liver of cirrhotic
rats. The administration of the VEGFR2 inhibitor markedly
reduced vascular hyperpermeability in the liver and mesentery
of these animals. In fact, extravasation of Evan’s Blue in these
organs was 3- and 2-fold lower in cirrhotic rats receiving
SU11248 than in those treated with vehicle (table 3).
DISCUSSION
The results of the current investigation indicate that hyperper-
meabilty selectively occurs in the liver and the mesenteric
vasculature, but not in the spleen, pancreas, small intestine or
kidney of cirrhotic rats. This is accompanied by a strong positive
signal for VEGF-A and Ang-2 in hepatic parenchymal cells and
paralleled by enhanced messenger and protein expression of
Figure 3 Representative western blots
for vascular endothelial growth factor-A
(VEGF-A) in the liver, mesentery and
pancreas of three control (CT) and three
cirrhotic rats with ascites (CH + A).
Densitometric analysis of all samples is
shown in the bottom right panel.
Figure 4 Representative western blots
for angiopoietin-2 (Ang-2) in the liver,
small intestine, pancreas and mesentery
of three control (CT) and three cirrhotic
rats with ascites (CH + A). Densitometric
analysis of all samples is shown in the
bottom right panel.
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these vascular permeability factors in both, liver and mesentery
of cirrhotic animals. Moreover, acute VEGFR2 blockade reduces
hepatic and mesenteric vascular permeability to nearly normal
values in cirrhotic rats. Altogether, these results indicate that
both VEGF-A and Ang-2 are involved in vascular hyperpermea-
biliy and the formation of ascites in experimental cirrhosis.
Histological examination of local leakage using colloidal
carbon confirmed that the cirrhotic liver and the mesentery
are hyperpermeable to macromolecules. In normal livers, the ink
was only found within the sinusoids, thus reflecting the
architectural integrity of the hepatic tissue. Narrowing and
collagenisation of the hepatic sinusoids were associated with a
strong presence of the marker close to the fibrous septa.
Previous studies have demonstrated that these areas are
surrounded by a dense and relatively immature vasculature,23 24
thus our results indicate that the increased vascular leakage in
the cirrhotic liver is a consequence of the previously described
angiogenic processes associated with fibrogenesis.23 Accordingly,
it is very likely that our observation of enhanced vascular
permeability in the mesenteric vasculature is also related to the
existence of ongoing angiogenesis in this territory. This would
be consistent with recent investigations demonstrating
increased abundance of CD31, a marker of endothelial cells, in
the mesentery of rats with portal hypertension as compared to
control rats.25 Conversely, the pancreas of cirrhotic animals
showed markedly decreased vascular permeability in compar-
ison to control rats. This finding was associated with impaired
vascularisation and decreased expression of VEGF-A and Ang-2.
As far we know, this is the first study describing diminished
pancreatic vessel density in experimental cirrhosis. Since
vascularisation of the pancreatic tissue is highly dependent on
proangiogenic signalling pathways,26 it is possible that disrup-
tion of these regulatory mechanisms by inflammatory sub-
stances produced in response to the hepatic injury3 result in the
islet vascularisation and permeability abnormalities observed in
cirrhotic rats. Furthermore, this could be a new mechanism
involved in the frequent impaired islet insulin output of patients
with liver disease.
Figure 5 Representative western blots
for angiopoietin-1 (Ang-1) in the liver,
small intestine pancreas and mesentery
of three control (CT) and three cirrhotic
rats with ascites (CH + A). Densitometric
analysis of all samples is shown in the
bottom right panel.
Figure 6 Representative images
corresponding to the
immunohistochemistry for vascular
endothelial growth factor-A (VEGF-A) in
the liver and pancreas of control rats and
cirrhotic rats with ascites.
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It is widely accepted that alterations in blood flow exert a
direct influence on microvascular permeability.27 Since cirrhotic
animals displayed increased total blood flow in the organs that
showed enhanced vascular permeability, the contributory role
of the hepatic and mesenteric hyperperfusion to the excessive
leakage observed in these territories cannot be excluded.
However, this is not the sole factor explaining this phenom-
enon. In fact, pancreas and small intestine of cirrhotic animals
showed enhanced total blood flow but reduced, or unaltered
vascular extravasation, respectively.
We found that mRNA and protein expression of the
permeability factors VEGF-A and Ang-2 rose in the liver and
the mesentery, but not in the spleen, pancreas, small intestine
and kidney of cirrhotic rats. Indeed, the former were those
showing significantly increased permeability values.
Immunolocalisation experiments revealed a strong positive
signal for both factors throughout the hepatic parenchyma of
cirrhotic animals. This probably results from the extensive
hypoxic areas previously described in the cirrhotic liver.23 28
Interestingly, we also found VEGF-A and Ang-2 expression in
normal hepatic tissue albeit restricted to the perivenular
hepatocytes, thus reflecting the lower partial pressure of oxygen
(PO2) surrounding these cells.
These data suggest a cooperative and dependent role for both,
VEGF-A and Ang-2, in the regulation of vascular permeability in
the liver and mesentery of cirrhotic animals. These two factors
are critical to explain vascular leakage in the cirrhotic tissues.
Both are expressed in response to hypoxia and VEGF-A
possesses a potent ability to permeate capillaries to a level
50 000-fold higher than histamine.29 Ang-2 is a receptor ligand
acting on endothelial cells which allows vascular remodelling by
antagonising angiopoietin-1 (Ang-1), a member of the same
family of molecules.30 Ang-1 induces capillary maturation which
then becomes quiescent and unresponsive to VEGF-A action
unless Ang-2 is also secreted.31 Hence, Ang-2 is an endogenous
Ang-1 antagonist that displaces Ang-1 from its receptor and
induces vessel destabilisation.14 Consequently, in a scenario in
which Ang-1 is activated, as occurs in the liver and mesentery of
cirrhotic rats, the concomitant activation of Ang-2 is a critical
event allowing vessel remodelling upon VEGF-A action. This is
in line with our findings showing that upregulation of Ang-1
and Ang-2, but not VEGF, does not result in vascular
hyperpermeability in the intestine of cirrhotic animals.
Endothelial cells exposed to VEGF-A allow passage of small
solutes by inducing the formation of fenestration and/or
caveolae.32 33 Leakage of larger proteins likely occurs between
adjacent endothelial cells.10 Disruption of cell-to-cell junctional
integrity results in extravasation of serum/plasma proteins,
leading to accumulation of fluids in the extracellular space.
VEGFR2 mediates regulation of junctional integrity and
constitutes a major mechanism for localised disruption by
VEGF-A.10 SU11248 is an indolinone molecule which has been
shown to possess potent antiangiogenic properties owing to its
selective inhibition of VEGFR2 and platelet derived growth
factor receptor-b (PDGFR-b) phosphorylation.34 This tyrosine
kinase inhibitor appears to be a powerful tool for elucidating the
contribution of VEGF-A activation to the increased vascular
permeability in cirrhosis since PDGFR-b is related to functions
other than regulation of vascular extravasation, including
pericyte recruitment and maturation of blood capillaries.14 In
Figure 7 Representative images
corresponding to the
immunohistochemistry for angiopoietin-2
(Ang-2) in the liver and pancreas of
control rats and cirrhotic rats with
ascites.
Table 3 Effect of vascular endothelial growth factor receptor 2
(VEGFR2) blockade on vascular leakage in cirrhotic rats with ascites
Tissue Cirrhotic rats (n = 5) Cirrhotic rats + SU11248 (n = 5)
Liver 148.2 (20.9) 59.7 (5.3)**
Mesentery 13.4 (2.2) 6.0 (1.0)*
Pancreas 10.1 (2.9) 17.9 (3.6)
Spleen 120.4 (12.4) 155.0 (21.2)
Small intestine 17.1 (2.9) 14.9 (2.5)
Kidney 118.3 (27.9) 65.3 (23.0)
Results (mean (SE)) are given for the regional vascular permeability (mg Evan’s Blue
per g tissue).
*p,0.01 and **p,0.001 vs control rats.
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fact, acute inhibition of VEGFR2 phosphorylation markedly
reduced vessel permeability in the liver and mesentery of
cirrhotic rats with ascites, further emphasising the importance
of this signalling pathway in the pathogenesis of vascular
leakage in experimental cirrhosis.
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